Latest Insider Transactions at P3 Health Partners Inc. (PIII)
This section provides a real-time view of insider transactions for P3 Health Partners Inc. (PIII). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of P3 Health Partners Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of P3 Health Partners Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 12
2023
|
Sherif Abdou Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
108,225
+50.0%
|
$216,450
$2.63 P/Share
|
|
Apr 06
2023
|
Chicago Pacific Founders Ugp, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,739,120
+4.33%
|
$4,739,120
$1.18 P/Share
|
|
Apr 06
2023
|
Leavitt Legacy, LLC |
BUY
Grant, award, or other acquisition
|
Indirect |
9,838,997
+50.0%
|
-
|
|
Apr 06
2023
|
Amir Bacchus Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
251,298
+50.0%
|
-
|
|
Apr 06
2023
|
Amir Bacchus Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,005,193
+50.0%
|
-
|
|
Jan 28
2022
|
Michael Balkin > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
15,000
+0.2%
|
$60,000
$4.83 P/Share
|
|
Dec 03
2021
|
Sherif Abdou Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
28,185,982
+50.0%
|
$13,219,225,558
$469.77 P/Share
|
|
Dec 03
2021
|
Amir Bacchus Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
3,758,130
+50.0%
|
$1,409,298,750
$375.81 P/Share
|
|
Dec 03
2021
|
Amir Bacchus Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,032,528
+50.0%
|
$22,593,889,584
$1503.25 P/Share
|
|
Dec 03
2021
|
Eric Atkins Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
450,517
+50.0%
|
$20,273,265
$45.05 P/Share
|
|
Dec 03
2021
|
Gregory N. Kazarian Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,177,659
+50.0%
|
$137,786,103
$117.77 P/Share
|
|
Dec 03
2021
|
Thomas Edmunds Price Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,177,659
+50.0%
|
$137,786,103
$117.77 P/Share
|
|
Oct 04
2021
|
Robert G Zimmerman Director |
BUY
Conversion of derivative security
|
Direct |
25,000
+50.0%
|
-
|
|
Oct 04
2021
|
John R Svoboda Director |
BUY
Conversion of derivative security
|
Direct |
25,000
+50.0%
|
-
|
|
Oct 04
2021
|
Foresight Sponsor Group, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
6,843,525
+47.63%
|
-
|
|
Oct 04
2021
|
Brian R Gamache Director |
BUY
Conversion of derivative security
|
Direct |
25,000
+50.0%
|
-
|
|
Oct 04
2021
|
Michael Balkin > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
6,843,525
+47.63%
|
-
|
|
Oct 04
2021
|
Gregory D Wasson Director |
BUY
Conversion of derivative security
|
Indirect |
6,843,525
+47.63%
|
-
|
|
Feb 12
2021
|
Gregory D Wasson Director |
BUY
Open market or private purchase
|
Indirect |
682,500
+50.0%
|
-
|
|
Feb 12
2021
|
Michael Balkin > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
682,500
+50.0%
|
-
|
|
Feb 12
2021
|
Foresight Sponsor Group, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
682,500
+50.0%
|
-
|